We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Amgen has agreed to acquire Five Prime Therapeutics, a South San Francisco biotech company, for $1.9 billion, a deal that will net the biopharma titan a pipeline that includes a promising investigational gastric cancer drug. Read More
Germany’s CureVac has partnered with pharma giant Novartis to potentially manufacture hundreds of millions of doses of the small company’s COVID-19 vaccine candidate, CVnCoV, which is now under review by the European Medicines Agency (EMA). Read More
Perrigo is transforming itself into a “consumer self-care” business, according to Murray Kessler, president and CEO of the Dublin, Ireland-based company. Read More
Ovid Therapeutics is selling the global rights to an investigational drug for rare epileptic diseases to Takeda Pharmaceutical in a deal worth potentially $856 million — as Ovid shifts gears and focuses on research of new neurological therapies. Read More
New Mexico’s attorney general has filed a lawsuit against Gilead Sciences, Teva Pharmaceuticals and Bristol Myers Squibb (BMS) over alleged anticompetitive practices that caused the state to significantly overpay for HIV medications. Read More
With Johnson & Johnson struggling to meet its COVID-19 vaccine supply commitments for the U.S., pharma titan Merck will provide its support to ramp up manufacturing of the one-shot vaccine, the Biden administration said Tuesday. Read More
Merck KGaA will pay Switzerland-based Debiopharm up to $1.08 billion (€900 million) for the global rights to Xevinapant, an investigational head and neck cancer treatment. Read More